Treatment of transgenic murine retinoblastoma with attenuated herpes virus

P. D. Imesch, C. R. Brandt, N. A. Syed, Daniel Albert

Research output: Contribution to journalArticle

Abstract

Purpose: To test the effect of a recombinant herpes simplex virus (HSV) attenuated for neurovirulence on growth and morphology of retinoblastoma in vivo. Methods: At the age of 16 weeks the right eye of 17 LHβ transgenic mice, a murine model for retinoblastoma, were injected with 106 pfu of an intertypic recombinant of HSV1 and HSV2, termed RE6. Mice were sacrificed 3 weeks later, eyes were enucleated and fixed in formalin. Tumor characteristics were graded on hematoxylin and eosin stained sections and the tumor area was measured by digital image analysis. The viral antigen HSV1 was identified using immunohistochemical staining with a polyclonal antibody. Viral titers were measured in 5 eyes from LHβ transgenic mice and in 5 eyes from normal mice at 1, 3, 5, 7 and 10 days after injection with 106 pfu of RE6 virus. Results: Tumor area was significantly smaller in treated compared to control eyes (p=0.038). Treated tumors were less differentiated (p=0.04) and showed fewer rosettes (p=0.049) than control tumors. Other morphologic changes were similar in both groups.The RE6 virus grew less well in LHβ transgenic mice but cleared by 7 days post infection in both groups of mice. Immunohistochemistry for the HSV1 antigen revealed focal areas of positive staining within the tumor and the retinal pigment epithelium in treated but not in control eyes. Conclusions: Attenuated herpesvirus is able to significantly reduce growth of an endogenously arising tumor and induces few other pathologic changes.

Original languageEnglish (US)
JournalInvestigative Ophthalmology and Visual Science
Volume37
Issue number3
StatePublished - Feb 15 1996
Externally publishedYes

Fingerprint

Retinoblastoma
Viruses
Neoplasms
Transgenic Mice
Therapeutics
Staining and Labeling
Viral Antigens
Retinal Pigment Epithelium
Herpesviridae
Simplexvirus
Hematoxylin
Eosine Yellowish-(YS)
Growth
Formaldehyde
Immunohistochemistry
Antigens
Injections
Antibodies
Infection

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Treatment of transgenic murine retinoblastoma with attenuated herpes virus. / Imesch, P. D.; Brandt, C. R.; Syed, N. A.; Albert, Daniel.

In: Investigative Ophthalmology and Visual Science, Vol. 37, No. 3, 15.02.1996.

Research output: Contribution to journalArticle

@article{fec93405cdbd44edaea84057745fc58a,
title = "Treatment of transgenic murine retinoblastoma with attenuated herpes virus",
abstract = "Purpose: To test the effect of a recombinant herpes simplex virus (HSV) attenuated for neurovirulence on growth and morphology of retinoblastoma in vivo. Methods: At the age of 16 weeks the right eye of 17 LHβ transgenic mice, a murine model for retinoblastoma, were injected with 106 pfu of an intertypic recombinant of HSV1 and HSV2, termed RE6. Mice were sacrificed 3 weeks later, eyes were enucleated and fixed in formalin. Tumor characteristics were graded on hematoxylin and eosin stained sections and the tumor area was measured by digital image analysis. The viral antigen HSV1 was identified using immunohistochemical staining with a polyclonal antibody. Viral titers were measured in 5 eyes from LHβ transgenic mice and in 5 eyes from normal mice at 1, 3, 5, 7 and 10 days after injection with 106 pfu of RE6 virus. Results: Tumor area was significantly smaller in treated compared to control eyes (p=0.038). Treated tumors were less differentiated (p=0.04) and showed fewer rosettes (p=0.049) than control tumors. Other morphologic changes were similar in both groups.The RE6 virus grew less well in LHβ transgenic mice but cleared by 7 days post infection in both groups of mice. Immunohistochemistry for the HSV1 antigen revealed focal areas of positive staining within the tumor and the retinal pigment epithelium in treated but not in control eyes. Conclusions: Attenuated herpesvirus is able to significantly reduce growth of an endogenously arising tumor and induces few other pathologic changes.",
author = "Imesch, {P. D.} and Brandt, {C. R.} and Syed, {N. A.} and Daniel Albert",
year = "1996",
month = "2",
day = "15",
language = "English (US)",
volume = "37",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "3",

}

TY - JOUR

T1 - Treatment of transgenic murine retinoblastoma with attenuated herpes virus

AU - Imesch, P. D.

AU - Brandt, C. R.

AU - Syed, N. A.

AU - Albert, Daniel

PY - 1996/2/15

Y1 - 1996/2/15

N2 - Purpose: To test the effect of a recombinant herpes simplex virus (HSV) attenuated for neurovirulence on growth and morphology of retinoblastoma in vivo. Methods: At the age of 16 weeks the right eye of 17 LHβ transgenic mice, a murine model for retinoblastoma, were injected with 106 pfu of an intertypic recombinant of HSV1 and HSV2, termed RE6. Mice were sacrificed 3 weeks later, eyes were enucleated and fixed in formalin. Tumor characteristics were graded on hematoxylin and eosin stained sections and the tumor area was measured by digital image analysis. The viral antigen HSV1 was identified using immunohistochemical staining with a polyclonal antibody. Viral titers were measured in 5 eyes from LHβ transgenic mice and in 5 eyes from normal mice at 1, 3, 5, 7 and 10 days after injection with 106 pfu of RE6 virus. Results: Tumor area was significantly smaller in treated compared to control eyes (p=0.038). Treated tumors were less differentiated (p=0.04) and showed fewer rosettes (p=0.049) than control tumors. Other morphologic changes were similar in both groups.The RE6 virus grew less well in LHβ transgenic mice but cleared by 7 days post infection in both groups of mice. Immunohistochemistry for the HSV1 antigen revealed focal areas of positive staining within the tumor and the retinal pigment epithelium in treated but not in control eyes. Conclusions: Attenuated herpesvirus is able to significantly reduce growth of an endogenously arising tumor and induces few other pathologic changes.

AB - Purpose: To test the effect of a recombinant herpes simplex virus (HSV) attenuated for neurovirulence on growth and morphology of retinoblastoma in vivo. Methods: At the age of 16 weeks the right eye of 17 LHβ transgenic mice, a murine model for retinoblastoma, were injected with 106 pfu of an intertypic recombinant of HSV1 and HSV2, termed RE6. Mice were sacrificed 3 weeks later, eyes were enucleated and fixed in formalin. Tumor characteristics were graded on hematoxylin and eosin stained sections and the tumor area was measured by digital image analysis. The viral antigen HSV1 was identified using immunohistochemical staining with a polyclonal antibody. Viral titers were measured in 5 eyes from LHβ transgenic mice and in 5 eyes from normal mice at 1, 3, 5, 7 and 10 days after injection with 106 pfu of RE6 virus. Results: Tumor area was significantly smaller in treated compared to control eyes (p=0.038). Treated tumors were less differentiated (p=0.04) and showed fewer rosettes (p=0.049) than control tumors. Other morphologic changes were similar in both groups.The RE6 virus grew less well in LHβ transgenic mice but cleared by 7 days post infection in both groups of mice. Immunohistochemistry for the HSV1 antigen revealed focal areas of positive staining within the tumor and the retinal pigment epithelium in treated but not in control eyes. Conclusions: Attenuated herpesvirus is able to significantly reduce growth of an endogenously arising tumor and induces few other pathologic changes.

UR - http://www.scopus.com/inward/record.url?scp=33750157742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750157742&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33750157742

VL - 37

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 3

ER -